Semaglutide Intermediate 29‑peptide, also known as the main chain of Semaglutide 29‑peptide, Semaglutide Intermediate P29, or GLP‑1(9‑37), is a key intermediate for the synthesis of semaglutide active pharmaceutical ingredient (API).
Semaglutide sodium is a long‑acting analogue of human glucagon‑like peptide‑1 (GLP‑1) and an agonist of the human GLP‑1 receptor. Semaglutide holds potential for research on type 2 diabetes mellitus.This product is a long‑acting GLP‑1 receptor agonist analogue produced by recombinant DNA technology and chemical modification. Compared with human GLP‑1, it has two amino acid substitutions: Ala8 is replaced by Aib8 (2‑aminoisobutyric acid), and Lys34 is replaced by Arg34. Acetylation with fatty diacid occurs at lysine‑26 to form semaglutide.
Semaglutide Intermediate 29‑peptide is manufactured via genetic engineering fermentation under GMP‑compliant conditions with high product purity. It is a lyophilized powder obtained from Escherichia coli‑recombinantly expressed semaglutide precursor through enzymatic cleavage, chromatographic purification and freeze‑drying.
Product Advantages
Animal-origin Free: Free of animal viruses, pathogenic substances and adventitious agent contamination for superior safety.
Regulatory Compliance: Production facilities and manufacturing environment comply with relevant regulations and GMP guidelines.
Complete Quality Documentation: Relevant regulatory supporting documents are available upon customer request.
ZJ26F0838725